# Curated AI beats frontier LLMs at pharma asset discovery

arXiv: https://arxiv.org/abs/2605.04908 · HTML: https://mlsanity.com/paper/2605.04908/

## Key facts

- No citing papers in the map yet (data through 14 Oct 2026).
- Builds on 3 of its 9 references that are in the map.
- First posted on arXiv 6 May 2026.

## Builds on (most cited first, 3 of 3)

- [Retrieval-Augmented Generation for Knowledge-Intensive NLP Tasks](https://mlsanity.com/paper/2005.11401/) (2020)
- [Judging LLM-as-a-Judge with MT-Bench and Chatbot Arena](https://mlsanity.com/paper/2306.05685/) (2023)
- [Survey of Hallucination in Natural Language Generation](https://mlsanity.com/paper/2202.03629/) (2022)

## Abstract (arXiv)

General-purpose LLMs with web search are increasingly used to scout the competitive landscape of pharmaceutical pipelines. We benchmark Gosset -- an AI platform with a chat interface backed by curated target-, modality-, and indication-level drug-asset annotations -- against four frontier systems with web access (Claude Opus 4.7, GPT 5.5, Gemini 3.1 Pro, Perplexity sonar-pro) on ten niche oncology/immunology targets where most of the pipeline lives in the long tail of preclinical and Asian-developed assets. All five systems receive the same natural-language query and the same JSON output schema. Across 10 targets Gosset returns 3.2x more verified drugs per query than the best frontier system, at perfect precision and 100% recall against the cross-system union of verified drugs. The same curated index is exposed as a Gosset MCP server that any frontier model can call as a tool, suggesting that each of these systems can close most of the recall gap by swapping generic web search for a curated index behind the same chat interface.